Barth C, Soares M, Toffart A C, Timsit J F, Burghi G, Irrazabal C, Pattison N, Tobar E, Almeida B F, Silva U V, Azevedo L C, Rabbat A, Lamer C, Parrot A, Souza-Dantas V C, Wallet F, Blot F, Bourdin G, Piras C, Delemazure J, Durand M, Salluh J, Azoulay E, Lemiale Virginie
Medical ICU, AP-HP, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010, Paris, France.
Post-Graduation Program, Instituto Nacional de Câncer, Rio de Janeiro Department of Clinical Research, D'Or Institute for Research and Education, Rio de Janeiro, Brazil.
Ann Intensive Care. 2018 Aug 4;8(1):80. doi: 10.1186/s13613-018-0426-2.
Although patients with advanced or metastatic lung cancer have poor prognosis, admission to the ICU for management of life-threatening complications has increased over the years. Patients with newly diagnosed lung cancer appear as good candidates for ICU admission, but more robust information to assist decisions is lacking. The aim of our study was to evaluate the prognosis of newly diagnosed unresectable lung cancer patients.
A retrospective multicentric study analyzed the outcome of patients admitted to the ICU with a newly diagnosed lung cancer (diagnosis within the month) between 2010 and 2013.
Out of the 100 patients, 30 had small cell lung cancer (SCLC) and 70 had non-small cell lung cancer. (Thirty patients had already been treated with oncologic treatments.) Mechanical ventilation (MV) was performed for 81 patients. Seventeen patients received emergency chemotherapy during their ICU stay. ICU, hospital, 3- and 6-month mortality were, respectively, 47, 60, 67 and 71%. Hospital mortality was 60% when invasive MV was used alone, 71% when MV and vasopressors were needed and 83% when MV, vasopressors and hemodialysis were required. In multivariate analysis, hospital mortality was associated with metastatic disease (OR 4.22 [1.4-12.4]; p = 0.008), need for invasive MV (OR 4.20 [1.11-16.2]; p = 0.030), while chemotherapy in ICU was associated with survival (OR 0.23, [0.07-0.81]; p = 0.020).
This study shows that ICU management can be appropriate for selected newly diagnosed patients with advanced lung cancer, and chemotherapy might improve outcome for patients with SCLC admitted for cancer-related complications. Nevertheless, tumors' characteristics, numbers and types of organ dysfunction should be taken into account in the decisional process before admitting these patients in ICU.
尽管晚期或转移性肺癌患者预后较差,但多年来因危及生命的并发症而入住重症监护病房(ICU)进行治疗的情况有所增加。新诊断的肺癌患者似乎是入住ICU的合适人选,但缺乏更有力的信息来辅助决策。我们研究的目的是评估新诊断的不可切除肺癌患者的预后。
一项回顾性多中心研究分析了2010年至2013年间因新诊断肺癌(确诊在当月内)入住ICU的患者的结局。
100例患者中,30例为小细胞肺癌(SCLC),70例为非小细胞肺癌。(30例患者已经接受了肿瘤治疗。)81例患者接受了机械通气(MV)。17例患者在ICU住院期间接受了紧急化疗。ICU死亡率、医院死亡率、3个月和6个月死亡率分别为47%、60%、67%和71%。单独使用有创MV时医院死亡率为60%,需要MV和血管升压药时为71%,需要MV、血管升压药和血液透析时为83%。多因素分析显示,医院死亡率与转移性疾病相关(比值比[OR]4.22[1.4 - 12.4];p = 0.008),需要有创MV相关(OR 4.20[1.11 - 16.2];p = 0.030),而ICU内化疗与生存相关(OR 0.23,[0.07 - 0.81];p = 0.020)。
本研究表明,ICU管理可能适用于部分新诊断的晚期肺癌患者,化疗可能改善因癌症相关并发症入住ICU的SCLC患者的结局。然而,在将这些患者收入ICU之前的决策过程中,应考虑肿瘤特征、器官功能障碍的数量和类型。